Results 91 to 100 of about 7,594,057 (369)

The atypical KRASQ22K mutation directs TGF‐β response towards partial epithelial‐to‐mesenchymal transition in patient‐derived colorectal cancer tumoroids

open access: yesMolecular Oncology, EarlyView.
TGF‐β has a complex role in cancer, exhibiting both tumor‐suppressive and tumor‐promoting properties. Using a series of differentiated tumoroids, derived from different stages and mutational background of colorectal cancer patients, we replicate this duality of TGF‐β in vitro. Notably, the atypical but highly aggressive KRASQ22K mutation rendered early‐
Theresia Mair   +17 more
wiley   +1 more source

Lung tumorspheres as a drug screening platform against cancer stem cells [PDF]

open access: yes, 2019
Treatment resistance and metastasis are linked to cancer stem cells (CSCs). This population represents a promising target, but remains unexplored in lung cancer.
Amado, H.   +12 more
core   +1 more source

Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids

open access: yesChinese Journal of Lung Cancer, 2016
Background and objective The incidence of pulmonary carcinoid (PC) is very rare in primary lung malignant tumors, and the prognosis of this disease is closely associated with its pathological features. In this study, the expressions of programmed death 1
Mingbiao LI   +8 more
doaj   +1 more source

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells

open access: yesMolecular Oncology, EarlyView.
Loss of the frequently mutated chromatin remodeler ARID1A, a subunit of the SWI/SNF cBAF complex, results in less open chromatin, alternative splicing, and the failure to stop cells from progressing through the cell cycle after DNA damage in bladder (cancer) cells. Created in BioRender. Epigenetic regulators, such as the SWI/SNF complex, with important
Rebecca M. Schlösser   +11 more
wiley   +1 more source

The Reversing and Molecular Mechanisms of miR-503 on the Drug-resistance 
to Cisplatin in A549/DDP Cells

open access: yesChinese Journal of Lung Cancer, 2014
Background and objective Cisplatin-resistance in lung cancer cells is general in clinic, hence it is significant to investigate the mechanisms of cisplatin-resistant and develop new methods of reversing drug-resistance.
Yi WU   +5 more
doaj   +1 more source

Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer

open access: yesDrug Delivery, 2021
Topotecan is potent anti-cancer drug approved for various malignancies but hematopoietic toxicities undermine its wider application and use of its most effective dose. This study aims to improve these limitations through inhalation-delivery.
Philip J. Kuehl   +8 more
doaj   +1 more source

Escape from TGF‐β‐induced senescence promotes aggressive hallmarks in epithelial hepatocellular carcinoma cells

open access: yesMolecular Oncology, EarlyView.
Chronic TGF‐β exposure drives epithelial HCC cells from a senescent state to a TGF‐β resistant mesenchymal phenotype. This transition is characterized by the loss of Smad3‐mediated signaling, escape from senescence, enhanced invasiveness and metastatic potential, and upregulation of key resistance modulators such as MARK1 and GRM8, ultimately promoting
Minenur Kalyoncu   +11 more
wiley   +1 more source

ANN for Predicting DNA Lung Cancer [PDF]

open access: yes, 2017
: Lung cancer is the top reason of cancer-associated deaths globally. Surgery is the typical treatment for early-stage non-small cell lung cancer (NSCLC).
Bashhar, Bastami   +4 more
core  

Current Status of Self-transcendence among Lung Cancer Patients 
and Its Influencing Factors

open access: yesChinese Journal of Lung Cancer
Background and objective Different degrees of self-transcendence exist in lung cancer patients, which can stimulate patients' self-awareness and promote them to face negative events in life positively, thus improving patients' quality of life and ...
Xue YANG   +4 more
doaj   +1 more source

Ensartinib as a neoadjuvant therapy for stage IIIA non-small cell lung cancer patients with EML4-ALK fusion: a case report and literature review

open access: yesFrontiers in Oncology
Anaplastic lymphoma kinase (ALK) inhibitors have shown efficacy in treating ALK-positive advanced non-small cell lung cancer (NSCLC) patients. However, the effectiveness of ensartinib neoadjuvant therapy remains ambiguous.
Hao Zhang   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy